ArticleJournal of contemporary brachytherapy2026
Clinical outcomes after interstitial high-dose-rate brachytherapy vs. stereotactic body radiotherapy in hepatocellular carcinoma: A retrospective matched single-center analysis.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Interstitial high-dose-rate brachytherapy (iBT) and stereotactic body radiotherapy (SBRT) are local treatment options for hepatocellular carcinoma (HCC). Data comparing their efficiency and safety profile remain limited. Therefore, we aimed to compare treatment results of iBT and SBRT in HCC patients. Material and methods: Patients with HCC who underwent iBT or SBRT between 2014 and 2024 at our tertiary center were retrospectively analyzed. Local control (LC), progression-free survival (PFS), and overall survival (OS) were evaluated. Treatment-related acute and chronic toxicities were assessed. Results: In a cohort of 92 patients with 125 HCC lesions, 60 patients (65.2%) with 86 lesions (68.8%) were treated with iBT. The median follow-up was 21 months. There were no significant differences in LC ( Conclusions: Both iBT and SBRT provide effective local treatment options for HCC, achieving comparable LC and PFS, while maintaining a manageable toxicity profile. Patient selection should be guided by institutional expertise and patient preference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.